Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by ronrydellon Aug 21, 2021 9:55am
249 Views
Post# 33744726

JD’s Part II post

JD’s Part II postAfter reading Jd's post five different times, and gleaning new information each time, I conclude that the naysayers that post negative things about both JD and Chrispi should really rethink there opinion of both of these posters and the information they are contributing.

The bottom line on the Part II recital is that this holding will probably be a very long hold in order to reach the share price it deserves. In fact it "could be" a colossal "ultra home run", or if it fails in human trails, the inflammation part, of course will go into the dust bowl of the many great try's in biotech,

Bottom line, this play deserves a sizable group of appropriate investors to hold 25K to 50K shares of this, at these prices, as a reasonable gamble with the caveat of holding, possibly for serveral more years....Happily the company is now in a strong cash position so they don't have to accept a low partners takeout and should be able to wait for more more quality licensing agreements.

Again, please join me in gratitude for all the hard work and research that JD has put in his Part II post, reread it again serveral times, look up the worlds you don't know as he has a great command of the English language, and patiently wait thru the rest of 2021 and into 2022-2024 for those of you that want a far better outcome of winning the lottery or blindly following other plays that aren't getting this kind of research that JD has done! I will look forward to subsequent posts from this talented man!
<< Previous
Bullboard Posts
Next >>